Premium
Cytochrome P450 2J2*7 polymorphisms in Japanese, Mongolians and Ovambos
Author(s) -
Takeshita Haruo,
Tsubota Etsuko,
Takatsuka Hisakazu,
Kunito Takashi,
Fujihara Junko
Publication year - 2008
Publication title -
cell biochemistry and function
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.933
H-Index - 61
eISSN - 1099-0844
pISSN - 0263-6484
DOI - 10.1002/cbf.1512
Subject(s) - genetics , genotype , cytochrome p450 , biology , polymorphism (computer science) , allele , allele frequency , arachidonic acid , gene , restriction fragment length polymorphism , metabolism , biochemistry , enzyme
Human cytochrome P450 2J2 (CYP2J2) is abundant in cardiovascular tissue and active in the metabolism of arachidonic acid to eicosanoids that have potent vasodilatory properties. Variability of the CYP2J2 gene is highly constrained except for its proximal promoter: there is a relatively common and functionally relevant single nucleotide polymorphism, indicated by −50G > T polymorphism ( CYP2J2*7 ). Although genetic variation is known among ethnic groups, data for allele frequency are limited to a few Caucasian, Asian, and one African populations. In the present study, genotype distribution of CYP2J2*7 polymorphisms was investigated using polymerase chain reaction and restriction fragment length polymorphism assay in Japanese ( n = 338), Mongolian ( n = 118), and Ovambo ( n = 186) populations and the findings compared with other populations. The mutant ( CYP2J2*7 ) frequencies in the Japanese, Mongolians, and Ovambos were 0.0621, 0.0339, and 0.0672, respectively. Except for the Taiwanese, a general uniformity in the polymorphism in the Asian populations was observed. The mutation frequency of Ovambos was relatively lower than that of the African‐American population. This study is the first to investigate the distribution of the CYP2J2*7 gene polymorphisms in Japanese, Mongolians, and Ovambos. These data will be informative and facilitate genetic association studies, in Asian and African populations for CYP2J2 ‐related diseases such as cardiovascular disorders. Copyright © 2008 John Wiley & Sons, Ltd.